139 related articles for article (PubMed ID: 3784612)
1. Immunological monitoring of clinical trials using biological response modifiers.
Maluish AE
Lymphokine Res; 1986; 5 Suppl 1():S183-7. PubMed ID: 3784612
[TBL] [Abstract][Full Text] [Related]
2. Assessment of biological responses: what to measure and when.
Maluish AE; Herberman RB
Cancer Treat Rep; 1985 Oct; 69(10):1165-9. PubMed ID: 3899356
[TBL] [Abstract][Full Text] [Related]
3. Design of clinical trials with biological response modifiers.
Herberman RB
Cancer Treat Rep; 1985 Oct; 69(10):1161-4. PubMed ID: 2412692
[TBL] [Abstract][Full Text] [Related]
4. Protocol design for lymphokine testing in clinical studies of human cancer.
Lotze MT; Rosenberg SA
Lymphokine Res; 1986; 5 Suppl 1():S177-81. PubMed ID: 3784611
[TBL] [Abstract][Full Text] [Related]
5. Cancer therapy by biological response modifiers.
Herberman RB
Arzneimittelforschung; 1987 Feb; 37(2A):246-50. PubMed ID: 2436633
[TBL] [Abstract][Full Text] [Related]
6. Immunological monitoring and clinical trials of biological response modifiers.
Baseler MW; Urba WJ
Cancer Chemother Biol Response Modif; 1991; 12():231-50. PubMed ID: 1931445
[No Abstract] [Full Text] [Related]
7. Biologicals and biological response modifiers: fourth modality of cancer treatment.
Oldham RK
Cancer Treat Rep; 1984 Jan; 68(1):221-32. PubMed ID: 6198081
[TBL] [Abstract][Full Text] [Related]
8. Biological Response Modifiers Programme and cancer chemotherapy.
Oldham RK
Int J Tissue React; 1982; 4(3):173-88. PubMed ID: 6183193
[TBL] [Abstract][Full Text] [Related]
9. Immunological monitoring and clinical trials of biological response modifiers.
Kopp WC; Holmlund JT; Urba WJ
Cancer Chemother Biol Response Modif; 1994; 15():226-86. PubMed ID: 7540029
[No Abstract] [Full Text] [Related]
10. Monitoring cellular immune responses to cancer immunotherapy.
Morse MA; Clay TM; Hobeika AC; Mosca PJ; Lyerly HK
Curr Opin Mol Ther; 2001 Feb; 3(1):45-52. PubMed ID: 11249731
[TBL] [Abstract][Full Text] [Related]
11. [Methods for evaluating biological response modifiers].
Harousseau JL
Bull Cancer; 1998 Dec; 85(12):993-6. PubMed ID: 9917552
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic properties of biological response modifiers. A discussion of preclinical and clinical studies.
Talmadge JE
Contrib Gynecol Obstet; 1989; 17():49-62. PubMed ID: 2495895
[No Abstract] [Full Text] [Related]
13. Biological response modifiers.
Clark JW
Cancer Chemother Biol Response Modif; 1988; 10():434-59. PubMed ID: 3079394
[No Abstract] [Full Text] [Related]
14. Practical considerations for the establishment of a screening procedure for the assessment of biological response modifiers.
Talmadge JE; Oldham RK; Fidler IJ
J Biol Response Mod; 1984; 3(1):88-109. PubMed ID: 6707701
[TBL] [Abstract][Full Text] [Related]
15. Immunological monitoring and clinical trials of biological response modifiers.
Urba WJ; Baseler MW
Cancer Chemother Biol Response Modif; 1988; 10():473-91. PubMed ID: 2484322
[No Abstract] [Full Text] [Related]
16. Immunological monitoring and clinical trials of biological response modifiers.
Urba WJ; Baseler MW
Cancer Chemother Biol Response Modif; 1990; 11():281-302. PubMed ID: 2121208
[No Abstract] [Full Text] [Related]
17. Biological response modifiers: preclinical and clinical results.
Talmadge JE; Clark J
Cancer Chemother Biol Response Modif; 1987; 9():454-72. PubMed ID: 3079413
[No Abstract] [Full Text] [Related]
18. Dendritic cell immunotherapy: mapping the way.
Figdor CG; de Vries IJ; Lesterhuis WJ; Melief CJ
Nat Med; 2004 May; 10(5):475-80. PubMed ID: 15122249
[TBL] [Abstract][Full Text] [Related]
19. Biological response modifiers: preclinical evaluation and clinical activity.
Smalley RV; Oldham RK
Crit Rev Oncol Hematol; 1984; 1(3):259-94. PubMed ID: 6085037
[TBL] [Abstract][Full Text] [Related]
20. Use of new biologic agents in clinical immunotherapy.
Leventhal BG
Cancer Treat Rep; 1980; 64(2-3):435-9. PubMed ID: 7407781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
